1 minute reading time (50 words)

Lilly's REYVOW™ (lasmiditan) C-V, the First and Only Medicine in a New Class of Acute Treatment for Migraine (ditan), Now Available for Prescription

Eli Lilly and Company announced today that REYVOW™ (lasmiditan) C-V 50 mg and 100 mg tablets, an oral medication for the acute treatment of migraine with or without aura in adults, is now available for prescription and will be available in pharmacies in the next few days.

Full story

Related Posts

Want more pain resources? Check out our library of on-demand education, upcoming events, and more.

Learn More